24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Gamida Cell
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:33
The AI post-hype era will be won below the model layer
17:21
AI is replacing programmers, but it can't replace electricians
16:52
While some tech giants cut jobs, Palo Alto Networks and Nvidia are hiring hundreds in Israel
15:09
The people saying goodbye to high-tech
More stories
Buzz
Most popular
Daily
Weekly
1
Israel searches for technology that could find soldiers and pilots who cannot call for help
2
Another 10 U.S. tankers are headed to Israel's Ben Gurion as airport delays mount
3
Former Palantir and Torq veterans raise $8 million Seed to secure the rise of AI agents
4
ServiceNow continues layoffs as it restructures around AI
5
Israel's Iron Dome and Arrow makers unlikely to reach the IPO market before 2027 as Tomer joins the queue
More news
Gamida Cell
5 stories about Gamida Cell
Gamida Cell announces $75 million financing with Highbridge Capital Management
16.02.21
|
CTech
The Israeli company is developing and commercializing cures for blood cancers and serious hematologic diseases
Gamida Cell Downprices Shares to Raise $50 Million Nasdaq IPO
28.10.18
|
Lilach Baumer
The Israel-based biotech company offered its shares at $8, below its previous intention of $13 to $15 per share
Novartis-Backed Gamida Downgrades Nasdaq IPO Expectations to $50-$60 Million
18.10.18
|
Lilach Baumer
The Jerusalem-based biotech company filed for a $69 million initial public offering in September but disclosed no pricing terms
Biotech Company Gamida Cell Files for $69 Million Nasdaq IPO
30.09.18
|
Dror Reich
The Jerusalem-based company develops cellular and immune therapies. Its lead product is a universal bone marrow transplant solution
Pharma Veteran Julian Adams takes Helm at Gamida Cell
21.11.17
|
Lilach Baumer
The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor